Category: SHFNF news

Catch up with the latest news and updates from the SHFNF.

Published on August 13th, 2015
Public

Entresto press release

Follow link
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm

Published on September 3rd, 2014
Public

New research- Angiotensin-Neprilysin Inhibitors

Angiotensin-Neprilysin Inhibitors versus Enalapril in heart failure

Follow this link for the full article:

http://www.nejm.org/doi/full/10.1056/NEJMoa1409077?query=featured_home&#t=abstract

Background
We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.

Full Text of Background…

Methods
In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.

Full Text of Methods…

Results
The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group.

Full Text of Results…

Conclusions
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.)

Full Text of Discussion…

Published on August 27th, 2014
Public

Heart Disease Improvement Plan 2014

The Heart Disease Improvement Plan sets out the priorities and actions to deliver improved prevention, treatment and care for all people in Scotland affected by heart disease.
The Heart Disease Improvement Plan sets out our continued ambition to deliver world-leading health and social care which is person-centred, clinically effective and safe.

The Plan identifies the key priorities and sets out why these issues are important. It identifies the key actions which if delivered will contribute towards improvement. The Plan also emphasizes the importance of being able to measure the impact of what we do and thereby demonstrate that change has happened.

The Plan identifies six priority areas for improvement. These priorities are:

1. Prevention of Cardiovascular Disease

2. Mental Health for Heart Disease

3. Secondary and Tertiary Care Cardiology

4. Heart Disease Management and Rehabilitation

5. Heart Failure

6. Arrhythmias